TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00418847
Drug: miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
Study: NCT02008864
Drug: Senna
Normalized name: Senna
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
Study: NCT01071694
Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
Normalized name: Interferon gamma 1-b
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving Betaferon according to routine clinical practice
Study: NCT03404960
Drug: Niraparib + Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
Study: NCT03404960
Drug: Niraparib + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
Study: NCT03487666
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
Study: NCT03980756
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT03980756
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT00864058
Drug: Gabapentin 400 mg capsules
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Actavis formulated products under fasting conditions
Study: NCT01474538
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (100 U/mL) administered by CSII pump
Study: NCT01474538
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (100 U/mL) administered by CSII pump
Study: NCT03155204
Drug: tiotropium pMDI
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT01261065
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
Study: NCT04585347
Drug: ALZ-801 170 mg Fasting
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04585347
Drug: ALZ-801 205 mg Fasting
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04585347
Drug: ALZ-801 342 mg Fasting
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03997006
Drug: IV Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Aminophylline (100 mg/8h)
Study: NCT03997006
Drug: IV Neostigmine Methylsulfate + Atropine Sulphate
Normalized name: Neostigmine Methylsulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
Study: NCT02429466
Drug: Guadecitabine (SGI-110)
Normalized name: Capecitabine
DrugBank: Guadecitabine (DB11918)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
Study: NCT02598310
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 260mg/m2 q3w
Study: NCT02598310
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
Study: NCT02145819
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151996
Drug: Methylphenidate + SPD503 (Guanfacine hydrochloride)
Normalized name: Guanfacine Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00151996
Drug: Amphetamine + SPD503
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02321540
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily.
Study: NCT03850535
Drug: Idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
Study: NCT03850535
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
Study: NCT03850535
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
Study: NCT01670435
Drug: Ciprofloxacin (BAYQ3939)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient treated with Ciproxan as a first line treatment in daily clinical practice
Study: NCT02547558
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol Breezhaler@ 300 mcg (1 inhalation)
Study: NCT01555333
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A flexible dose titration will be utilized. Orally disintegrating tablets
Study: NCT00429533
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00266097
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
Study: NCT00266097
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
Study: NCT00266097
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
Study: NCT00266097
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
Study: NCT00266097
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
Study: NCT01929980
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02254655
Drug: Puerarin injection 400 mg
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
Study: NCT02254655
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
Study: NCT01065272
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days
Study: NCT03307746
Drug: Varlilumab
Normalized name: Varlilumab
DrugBank: Varlilumab (DB11930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27.
Study: NCT03460353
Drug: Dexamphetamine
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are tested for their normal prescription dexamphetamine medication
Study: NCT01739556
Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Normalized name: Anacin Aspirin Regimen Pill
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00431743
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00044915
Drug: Repinotan HCl (BAYX3702)
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Repinotan (DB06506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive 1.25 mg of repinotan
Study: NCT03701919
Drug: Botulinum toxin pyloroplasty
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
Study: NCT03701919
Drug: Normal saline pyloric injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
Study: NCT01394913
Drug: Reumatocept (etanercept)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg each week for 30 weeks
Study: NCT01394913
Drug: Enbrel (etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg each week for 30 weeks
Study: NCT02785068
Drug: MM-151
Normalized name: manganese sulfate 0.151 MG/ML
DrugBank: Manganese citrate (DB14495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligoclonal antibody
Study: NCT02785068
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03521245
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard Trastuzumab treatment regimen recommended for breast cancer
Study: NCT00945477
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800 mg daily x 12 weeks
Study: NCT02013232
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02453529
Drug: WCK 4873
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02312440
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Study: NCT02312440
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Study: NCT02312440
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure.
Study: NCT00225992
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00491543
Drug: ALT-2074
Normalized name: ALT-2074
DrugBank: ALT-2074 (DB05631)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00578695
Drug: lixivaptan
Normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04484688
Drug: perindopril-bisoprolol
Normalized name: perindopril, bisoprolol and amlodipine
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: outpatients with permanent atrial fibrillation and with preserved ejection fraction
Study: NCT02876146
Drug: Benzimidazole
Normalized name: Benzimidazole
DrugBank: Benzimidazole (DB02962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
Study: NCT03047733
Drug: Topical tacrolimus 0.1% ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
Study: NCT00253214
Drug: galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00230542
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
Study: NCT00230542
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
Study: NCT02397889
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
Study: NCT02397889
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
Study: NCT01112072
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
Study: NCT02800161
Drug: Trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose 70g/die
Study: NCT02258295
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline
Study: NCT03424928
Drug: Pomalidomide 4 MG Oral Capsule
Normalized name: Pomalidomide 4 mg oral capsule
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per os,capsule,4mg,1 capsule per period
Study: NCT03424928
Drug: Pomalidomide 4 MG Oral Capsule-Pomalyst
Normalized name: pomalidomide Oral Capsule [Pomalyst]
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per os,capsule,4mg,1 capsule per period
Study: NCT04018417
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug concentration: 0.255 μg/mL
Study: NCT01608594
Drug: administration of ipilimumab10mg/kg
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Study: NCT03385525
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00033111
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01445080
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00148876
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
Study: NCT02069392
Drug: Nicotine polacrilex lozenge
Normalized name: Nicotine 2 mg ORAL LOZENGE [Nicotine Polacrilex Lozenge Mint]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Of interest are the effects of nicotine on cognitive remediation training benefits.
Study: NCT02922426
Drug: ALKS 3831
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing for 21 consecutive days
Study: NCT02922426
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dosing for 21 consecutive days
Study: NCT00305630
Drug: Periocular injection of triamcinolone acetonide 40mg
Normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02757118
Drug: Intravenous Crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT02757118
Drug: Intravenous HES
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT01363479
Drug: Oral palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01363479
Drug: I.V. palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01363479
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00363285
Drug: cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766167
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low
Study: NCT01766167
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Middle
Study: NCT01766167
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High
Study: NCT01766167
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple
Study: NCT00587132
Drug: Synthetic Human Secretin
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mcg/kg one time dose.